Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

“…The primary endpoint of FURLONG study was IRCassessed PFS in the full analysis set (FAS) population, which had been published. 10 This preplanned analysis was done in patients with CNS lesions at baseline by IRC per RECIST version 1.1. The assessments of this report included CNS PFS, CNS ORR, CNS disease control rate (DCR), CNS duration of response (DoR), and CNS depth of response (DepOR).…”

“…In the phase 3 FURLONG study, furmonertinib had superior efficacy over gefitinib regarding PFS (20.8 versus 11.1 mo, hazard ratios [HRs] 0.44 [95% confidence interval [CI]: 0.34-0.58], p < 0.0001) in treatment-naive patients with NSCLC harbouring EGFR-sensitizing mutations. 10 Here, we report the CNS efficacy of furmonertinib versus gefitinib in the FURLONG study.…”

“…EGFR-sensitizing mutations are the most detected driven mutation in NSCLC, which can be as high as 46.3% in Asian patients with advanced stage adenocarcinoma, 2 and EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line treatment on the basis of the results of well-designed randomized controlled trials. [3][4][5][6][7][8][9][10] Third-generation EGFR TKIs were primarily developed to overcome a secondary EGFR T790M mutation causing resistance post firstor secondgeneration EGFR TKI treatment and found to have superior efficacy compared with first-generation EGFR TKIs in first-line settings. [8][9][10] The frequency of brain metastases is reported to be 25% during the course of NSCLC and to be 48% to 50% in patients with EGFR-sensitizing mutations.…”

“…[3][4][5][6][7][8][9][10] Third-generation EGFR TKIs were primarily developed to overcome a secondary EGFR T790M mutation causing resistance post firstor secondgeneration EGFR TKI treatment and found to have superior efficacy compared with first-generation EGFR TKIs in first-line settings. [8][9][10] The frequency of brain metastases is reported to be 25% during the course of NSCLC and to be 48% to 50% in patients with EGFR-sensitizing mutations. 11 As EGFR TKIs are the first choice to treat EGFR-sensitizing mutated NSCLC, developing drugs with brain penetration is of high importance.…”

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization

“…Tyrosine kinase inhibitors (TKIs) targeting mutant EGFR have brought great survival benefits to patients. With the progresses of drug development, third-generation TKIs, including osimertinib, aumolertinib and furmonertinib, have been recommended as the first-line setting for EGFR mutant NSCLC patients, 1 , 2 , 3 as salvage treatment for T790M mutation-positive patients after resistance to first- and second-generation EGFR TKIs 4 , 5 , 6 , 7 and as adjuvant therapy for post-surgery EGFR-mutant NSCLCs. 8 Other developing third-generation TKIs, including lazertinib, 9 abivertinib, 10 and rezivertinib 11 have shown powerful anti-tumor potentials in T790M-positive NSCLC patients.…”